219 related articles for article (PubMed ID: 27317413)
1. Drug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive Medications.
Smolders EJ; de Kanter CT; de Knegt RJ; van der Valk M; Drenth JP; Burger DM
Clin Pharmacokinet; 2016 Dec; 55(12):1471-1494. PubMed ID: 27317413
[TBL] [Abstract][Full Text] [Related]
2. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
3. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden K; Back D
Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents.
Murray M
Clin Pharmacokinet; 2023 Oct; 62(10):1365-1392. PubMed ID: 37731164
[TBL] [Abstract][Full Text] [Related]
5. Psychiatric treatment considerations with direct acting antivirals in hepatitis C.
Sockalingam S; Tseng A; Giguere P; Wong D
BMC Gastroenterol; 2013 May; 13():86. PubMed ID: 23672254
[TBL] [Abstract][Full Text] [Related]
6. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
Rodríguez-Torres M
Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
[TBL] [Abstract][Full Text] [Related]
7. Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation?
Smolders EJ; Pape S; de Kanter CT; van den Berg AP; Drenth JP; Burger DM
Int J Antimicrob Agents; 2017 Mar; 49(3):379-382. PubMed ID: 28185946
[TBL] [Abstract][Full Text] [Related]
8. Drug interactions with new hepatitis C oral drugs.
Soriano V; Labarga P; Barreiro P; Fernandez-Montero JV; de Mendoza C; Esposito I; Benítez-Gutiérrez L; Peña JM
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):333-41. PubMed ID: 25553890
[TBL] [Abstract][Full Text] [Related]
9. High frequency of potential interactions between direct-acting antivirals and concomitant therapy in HIV/hepatitis C virus-coinfected patients in clinical practice.
Macías J; Monge P; Mancebo M; Merchante N; Neukam K; Real LM; Pineda JA
HIV Med; 2017 Aug; 18(7):445-451. PubMed ID: 27882706
[TBL] [Abstract][Full Text] [Related]
10. Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection.
Néant N; Solas C
Int J Antimicrob Agents; 2020 Jul; 56(1):105571. PubMed ID: 30394302
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Risk Management and Hepatitis C: Combining Drugs.
Smolders EJ; Ter Horst PJG; Wolters S; Burger DM
Clin Pharmacokinet; 2019 May; 58(5):565-592. PubMed ID: 30259390
[TBL] [Abstract][Full Text] [Related]
12. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs).
Scavone C; Sportiello L; Rafaniello C; Mascolo A; Sessa M; Rossi F; Capuano A
Expert Opin Drug Saf; 2016 Dec; 15(sup2):85-100. PubMed ID: 27875916
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment.
Smolders EJ; de Kanter CT; van Hoek B; Arends JE; Drenth JP; Burger DM
Drug Saf; 2016 Jul; 39(7):589-611. PubMed ID: 27098247
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies.
Shahid I; ALMalki WH; Hafeez MH; Hassan S
Crit Rev Microbiol; 2016 Aug; 42(4):535-47. PubMed ID: 25373616
[TBL] [Abstract][Full Text] [Related]
15. State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015.
Lu CY; Zhang F; Golonski N; Lupton C; Jeffrey P; Wagner AK
Value Health; 2018 Jun; 21(6):692-697. PubMed ID: 29909874
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and risks from drug-to-drug interactions of new antivirals for chronic hepatitis C.
Binda C; Tortora A; Garcovich M; Annicchiarico BE; Siciliano M
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(1 Suppl):102-111. PubMed ID: 28379589
[TBL] [Abstract][Full Text] [Related]
17. Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection.
Ottman AA; Townsend ML; Hashem MG; DiMondi VP; Britt RB
Ann Pharmacother; 2018 Aug; 52(8):763-768. PubMed ID: 29577765
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antiviral interactions with opioids, alcohol or illicit drugs of abuse in HCV-infected patients.
Ing Lorenzini K; Girardin F
Liver Int; 2020 Jan; 40(1):32-44. PubMed ID: 31654604
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a specialty hepatitis C virus telephone pharmacy service.
Sabourin AA; Fisher-Grant KK; Saulles AR; Mohammad RA
Am J Health Syst Pharm; 2021 May; 78(Supplement_2):S38-S45. PubMed ID: 33684928
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic HCV genotype 1 coinfection.
Boesecke C; Rockstroh JK
Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
